| 10.51 2.5 (31.21%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.35 |
1-year : | 14.43 |
| Resists | First : | 10.57 |
Second : | 12.35 |
| Pivot price | 6.61 |
|||
| Supports | First : | 7.29 |
Second : | 5.26 |
| MAs | MA(5) : | 7.5 |
MA(20) : | 6.54 |
| MA(100) : | 4.47 |
MA(250) : | 4.43 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 89.5 |
D(3) : | 68.8 |
| RSI | RSI(14): 85.4 |
|||
| 52-week | High : | 10.57 | Low : | 2.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLNN ] has closed It is unclear right now based on current values. 228.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.59 - 10.62 | 10.62 - 10.65 |
| Low: | 7.72 - 7.75 | 7.75 - 7.78 |
| Close: | 10.44 - 10.5 | 10.5 - 10.57 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Mon, 15 Sep 2025
Clene Inc. Reports Q2 2025 Financial Results - MSN
Wed, 10 Sep 2025
Benchmark lowers Clene stock price target to $31 on funding concerns - Investing.com
Thu, 04 Sep 2025
36% Metabolite Improvement: Clene's CNM-Au8 Drug Shows Breakthrough in Parkinson's Disease Treatment - Stock Titan
Tue, 02 Sep 2025
Neurodegenerative Disease Biotech Clene to Showcase ALS and MS Pipeline at Major Investment Conference - Stock Titan
Thu, 14 Aug 2025
Clene's ALS Treatment Shows Survival Benefits, Plans FDA Filing as Cash Position Strengthens - Stock Titan
Thu, 14 Aug 2025
Clene Inc. Announces Q2 2025 Financial Results and Plans for FDA Meetings on CNM-Au8® Development in ALS and MS - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 7.17e+006 (%) |
| Held by Institutions | 30.8 (%) |
| Shares Short | 212 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.483e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 718.5 % |
| Return on Equity (ttm) | -52.9 % |
| Qtrly Rev. Growth | 286000 % |
| Gross Profit (p.s.) | -113.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 370968 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.25 |
| Dividend | 0 |
| Forward Dividend | 342060 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|